Mutant protein in Huntington disease is resistant to proteolysis in affected brain

被引:70
作者
Dyer, RB
McMurray, CT
机构
[1] Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Mol Neurosci Program, Rochester, MN 55905 USA
关键词
D O I
10.1038/ng745
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The cause of Huntington disease pathophysiology is unknown, but a major hypothesis suggests that toxicity arises from the cleavage and accumulation of amino-terminal fragments containing an expanded polyglutamine region. In evaluating huntingtin protein (HD) from human brain, transgenic animals and cells, we observed, unexpectedly, that mutant HD is more resistant to proteolysis than normal HD. The N-terminal cleavage fragments we observed arise from the processing of normal HD and are sequestered by full-length mutant HD. Our results support a model in which inhibition of proteolysis of mutant HD leads to aggregation and toxicity through the sequestering of important targets, including normal HD.
引用
收藏
页码:270 / 278
页数:9
相关论文
共 48 条
[21]   Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats [J].
Li, SH ;
Li, XJ .
HUMAN MOLECULAR GENETICS, 1998, 7 (05) :777-782
[22]   A cellular model that recapitulates major pathogenic steps of Huntington's disease [J].
Lunkes, A ;
Mandel, JL .
HUMAN MOLECULAR GENETICS, 1998, 7 (09) :1355-1361
[23]   Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice [J].
Mangiarini, L ;
Sathasivam, K ;
Seller, M ;
Cozens, B ;
Harper, A ;
Hetherington, C ;
Lawton, M ;
Trottier, Y ;
Lehrach, H ;
Davies, SW ;
Bates, GP .
CELL, 1996, 87 (03) :493-506
[24]   Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates [J].
Martindale, D ;
Hackam, A ;
Wieczorek, A ;
Ellerby, L ;
Wellington, C ;
McCutcheon, K ;
Singaraja, R ;
Kazemi-Esfarjani, P ;
Devon, R ;
Kim, SU ;
Bredesen, DE ;
Tufaro, F ;
Hayden, MR .
NATURE GENETICS, 1998, 18 (02) :150-154
[25]   REGULATED EXPRESSION OF THE PRODYNORPHIN GENE IN THE R2C LEYDIG TUMOR-CELL LINE [J].
MCMURRAY, CT ;
DEVI, L ;
CALAVETTA, L ;
DOUGLASS, JO .
ENDOCRINOLOGY, 1989, 124 (01) :49-59
[26]   Tissue-specific proteolysis of huntingtin (htt) in human brain: Evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum [J].
Mende-Mueller, LM ;
Toneff, T ;
Hwang, SR ;
Chesselet, MF ;
Hook, VYH .
JOURNAL OF NEUROSCIENCE, 2001, 21 (06) :1830-1837
[27]   A molecular investigation of true dominance in Huntington's disease [J].
Narain, Y ;
Wyttenbach, A ;
Rankin, J ;
Furlong, RA ;
Rubinsztein, DC .
JOURNAL OF MEDICAL GENETICS, 1999, 36 (10) :739-746
[28]   Interference by Huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity [J].
Nucifora, FC ;
Sasaki, M ;
Peters, MF ;
Huang, H ;
Cooper, JK ;
Yamada, M ;
Takahashi, H ;
Tsuji, S ;
Troncoso, J ;
Dawson, VL ;
Dawson, TM ;
Ross, CA .
SCIENCE, 2001, 291 (5512) :2423-2428
[29]   Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease [J].
Ona, VO ;
Li, MW ;
Vonsattel, JPG ;
Andrews, LJ ;
Khan, SQ ;
Chung, WM ;
Frey, AS ;
Menon, AS ;
Li, XJ ;
Stieg, PE ;
Yuan, JY ;
Penney, JB ;
Young, AB ;
Cha, JHJ ;
Friedlander, RM .
NATURE, 1999, 399 (6733) :263-267
[30]   DIFFERENTIAL LOSS OF STRIATAL PROJECTION NEURONS IN HUNTINGTON DISEASE [J].
REINER, A ;
ALBIN, RL ;
ANDERSON, KD ;
DAMATO, CJ ;
PENNEY, JB ;
YOUNG, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (15) :5733-5737